Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
Date:11/12/2008

LA JOLLA, Calif., Nov. 12 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced financial results for the third quarter ended September 30, 2008. For the three-month period, the Company posted revenue of $1.2 million and a net loss of $5.4 million. Cash and cash equivalents totaled $14.3 million at September 30, 2008.

"The past several months have been extremely productive as we further our transition to a development-only company," said Ev Graham, acting Chief Executive Officer of TorreyPines Therapeutics. "We held a successful End of Phase II meeting with the U.S. Food & Drug Administration (FDA) for tezampanel and believe we are well positioned to seek a corporate partner to continue its development. In addition, we continued to execute on our strategic plan by completing three transactions involving some of the Company's non-core assets. Looking ahead, we are on track to announce results from two clinical trials by the end of the year."

Upcoming Clinical Milestones:

-- Results from a Phase I clinical trial to evaluate the analgesic effect of NGX426, the oral prodrug of tezampanel, are on schedule to be announced in December 2008. The study is designed to evaluate the effect of NGX426 on hyperalgesia, an abnormally increased pain state, and allodynia, pain resulting from normally non-painful stimuli, when induced by intradermal injections of capsaicin.

-- Results from a Phase IIa study evaluating NGX267, a muscarinic agonist, as a potential treatment for xerostomia, are on schedule to be announced in December 2008. This study is designed to evaluate three doses of NGX267 and placebo in a four-way cross-over design in patients with xerostomia secondary to Sjogren's syndrome. The focus
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
2. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
3. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
4. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
5. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
6. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
7. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
8. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
9. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
10. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
11. TorreyPines Therapeutics Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 PharmaBoardroom,s new report, ... and available for free download , digs deep into ... growth in the sector today. One area where ... been in developing a homegrown pharmaceutical manufacturing base, even if ... remains some way off. A cursory comparison with neighboring ...
(Date:12/24/2014)... , Dec. 23, 2014  NeuroLifeSciences announced today ... in children with attention deficit/hyperactivity disorder published in ... The paper, titled "Pilot Phase 2 ... ( Konofal et al, Drug Des Devel ... shows that mazindol might be an effective, well-tolerated, ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ - RepliCel Life ... regenerative medicine company focused on the development of autologous ... out of the University of Calgary in conjunction with ... Carolina, which further validates the company,s ongoing clinical research ... effects of pattern baldness. The paper entitled ...
(Date:12/22/2014)... Calif. , Dec. 22, 2014  ( www.competitivehealth.com ... CoPatient, an online medical bill review and advocacy service, ... in the FREE WellCard Savings discount health services marketplace. ... bill that was more than they expected to pay. ... reduce health care costs, WellCard Savings is pleased to ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... June 24 ,WuXi PharmaTech (NYSE: WX ) ... announced,that the two companies have entered into a ... which will provide world-class preclinical,contract research services in ... located in a 323,450 square-foot, purpose-built facility in,Suzhou, ...
... The Board of,Directors of Schering-Plough Corporation (NYSE: ... per common share. Payment will be made on,Aug. 26, ... business on Aug.,1, 2008. As of March 31, 2008, ... Directors today also declared a quarterly dividend of,$3.75 per ...
... Sun Pharmaceutical,Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: ... Levitt, Chairman of the Board,of Directors of Taro Pharmaceutical ... Levitt,s letter of June 19, 2008 to Taro,s,shareholders, his ... the Initiating,Motion filed by Taro in the Tel-Aviv District ...
Cached Biology Technology:Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China 2Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China 3Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China 4Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 2Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 3Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 4Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 5Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 6Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 7
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
(Date:12/3/2014)... 2014 As part of our commitment to ... pleased to announce the release of a new reader ... the workforce data that they need. The ... by existing readers. Many such devices have serious shortcomings ... technology. Older models force users to navigate numerous complicated ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Inception Technologies to Release New Biometric Reader 2
... every day, especially wine, may be associated with an ... Dutch researchers who reported the findings of their study ... on Cardiovascular Disease Epidemiology and Prevention. , The researchers ... less than one glass per day) was associated with ...
... the University of Pennsylvania School of Medicine have discovered ... replication within cells -- use proteins that act as ... structure. If microtubules are not formed properly such basic ... which may have implications in such disease processes as ...
... on Mars do not drill deep enough to find the ... surface of Mars, according to research led by UCL (University ... that life once existed on Mars, cellular life could not ... the surface of Mars than a few metres deep ?beyond ...
Cached Biology News:Light wine intake is associated with longer life expectancy in men 2Light wine intake is associated with longer life expectancy in men 3Light wine intake is associated with longer life expectancy in men 4Molecular motors and brakes work together in cells 2Dig deeper to find Martian life 2Dig deeper to find Martian life 3
... Reagent B - Permeabilisation medium LEUCOPERM ... suspension with Reagent A and then permeabilising ... gives antibodies access to intracellular structures and ... cells intact. Specific formulations reduce background staining ...
...
Collected from calves that are 10 days old or less. Sterile, cell culture tested, US Origin...
Dako Target Retrieval Solution, Citrate pH 6 (x 10) For more information, please visit Dako' web-site. EU regulatory status: CE US regulatory status: IVD...
Biology Products: